155 related articles for article (PubMed ID: 11583476)
1. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.
Gobburu JV; Tammara V; Lesko L; Jhee SS; Sramek JJ; Cutler NR; Yuan R
J Clin Pharmacol; 2001 Oct; 41(10):1082-90. PubMed ID: 11583476
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
Polinsky RJ
Clin Ther; 1998; 20(4):634-47. PubMed ID: 9737824
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.
Cutler NR; Polinsky RJ; Sramek JJ; Enz A; Jhee SS; Mancione L; Hourani J; Zolnouni P
Acta Neurol Scand; 1998 Apr; 97(4):244-50. PubMed ID: 9576639
[TBL] [Abstract][Full Text] [Related]
5. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.
Hossain M; Jhee SS; Shiovitz T; McDonald C; Sedek G; Pommier F; Cutler NR
Clin Pharmacokinet; 2002; 41(3):225-34. PubMed ID: 11929322
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Jann MW; Shirley KL; Small GW
Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
[TBL] [Abstract][Full Text] [Related]
7. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
Kennedy JS; Polinsky RJ; Johnson B; Loosen P; Enz A; Laplanche R; Schmidt D; Mancione LC; Parris WC; Ebert MH
J Clin Psychopharmacol; 1999 Dec; 19(6):513-21. PubMed ID: 10587286
[TBL] [Abstract][Full Text] [Related]
8. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
Darreh-Shori T; Hellström-Lindahl E; Flores-Flores C; Guan ZZ; Soreq H; Nordberg A
J Neurochem; 2004 Mar; 88(5):1102-13. PubMed ID: 15009666
[TBL] [Abstract][Full Text] [Related]
10. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
Modrego PJ; Pina MA; Fayed N; Díaz M
CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
[TBL] [Abstract][Full Text] [Related]
11. Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration.
Tse FL; Laplanche R
Pharm Res; 1998 Oct; 15(10):1614-20. PubMed ID: 9794506
[TBL] [Abstract][Full Text] [Related]
12. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
14. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
Enz A; Gentsch C
Neuropharmacology; 2004 Sep; 47(3):408-13. PubMed ID: 15275830
[TBL] [Abstract][Full Text] [Related]
16. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Ballard CG
Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
[TBL] [Abstract][Full Text] [Related]
17. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
Stefanova E; Blennow K; Almkvist O; Hellström-Lindahl E; Nordberg A
Neurosci Lett; 2003 Feb; 338(2):159-63. PubMed ID: 12566177
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease.
Rompicherla SKL; Arumugam K; Bojja SL; Kumar N; Rao CM
Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1737-1755. PubMed ID: 34086100
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine for Alzheimer's disease.
Birks J; Iakovidou V; Tsolaki M
Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.
Shua-Haim J; Smith J; Picard F; Sedek G; Athalye S; Pommier F; Lefèvre G
Clin Drug Investig; 2008; 28(6):361-74. PubMed ID: 18479178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
